The Impact of Activity Promoting Video Games on Glycemic Control in Gestational Diabetes Mellitus
1 other identifier
interventional
150
0 countries
N/A
Brief Summary
Gestational diabetes mellitus (GDM) affects up to 3-5% of all pregnancies. When diagnosed with GDM, women undergo nutritional counseling, blood sugars monitoring and are encouraged to exercise regularly. Women who do not meet therapeutic targets may need to add insulin injections. Activity promoting video games are an attractive possibility for improvement of exercise compliance. The objective of this study is to determine whether providing women recently diagnosed with GDM with a Nintendo Wii™ activity promoting gaming platform will increase activity levels, improve glycemic control of sugar levels and decrease the need for supplementary insulin treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jul 2010
Longer than P75 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 27, 2010
CompletedFirst Submitted
Initial submission to the registry
February 3, 2017
CompletedFirst Posted
Study publicly available on registry
March 8, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2022
CompletedApril 29, 2020
April 1, 2020
12 years
February 3, 2017
April 28, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Glucose levels
Mean fasting and post-prandial glucose levels
Measured from study intake date until 36 weeks gestation
Secondary Outcomes (3)
Insulin therapy
Measured from study intake date until 36 weeks gestation
Activity level
Measured from study intake date until 36 weeks gestation
Maternal weight gain
Weight gained during pregnancy, measured from start of pregnancy (1 week gestation) to end of pregnancy (up to 40 weeks gestation).
Study Arms (2)
Control Group
NO INTERVENTIONParticipants in this group will receive diabetic care and education as per the standard of care. They will also be given a pedometer and will be instructed to record their number of steps at the end of each day
Wii Group
ACTIVE COMPARATORParticipants in this group will receive diabetic care and education as per the standard of care. They will also be given a Wii console and game to take home. Participants will be instructed on how to set up and use the Wii. These participants will also be given a pedometer and will be instructed to record their number of steps at the end of each day.
Interventions
Participants in the Wii group will be given a Wii console and video game to take home. The console includes a Wii balance board and remote controller. The Wii Fit game allows participants to choose different types of exercise such as yoga, aerobics, balance training, and more. Participant movements are shown on screen as they move with the balance board and remote control.
Eligibility Criteria
You may qualify if:
- Women diagnosed with gestational diabetes and a singleton pregnancy at 24-36 weeks of gestation.
You may not qualify if:
- Multiple gestation
- Pre-gestational diabetes
- Unable to provide informed consent
- Any contraindication to performing physical activity in pregnancy (e.g. increased risk of preterm delivery)
- Has and regularly uses a Nintendo Wii console
- Presence of co-morbidities including: Hypertension (systolic pressure \> 160 mmHg and/or diastolic pressure \> 100 mmHg), alcohol abuse (i.e. 2 glasses alcohol or more per day); drug abuse, use of the medication that affects insulin secretion or insulin sensitivity (antiviral, corticosteroids, antihypertensive drugs, all concomitant medication will be discussed); serious pulmonary (COPD, exercise induced asthma), cardiac, hepatic or renal (serum creatinine \> 150 μmol/l) impairment; malignant disease; serious mental or physical impairment (limiting the ability to understand or implement the study protocol).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Howard Berger, MD
Unity Health Toronto
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 3, 2017
First Posted
March 8, 2017
Study Start
July 27, 2010
Primary Completion
August 1, 2022
Study Completion
August 1, 2022
Last Updated
April 29, 2020
Record last verified: 2020-04
Data Sharing
- IPD Sharing
- Will not share